Exelixis Inc
(NAS:EXEL)
$
35.8372
-0.0128 (-0.04%)
Market Cap: 10.23 Bil
Enterprise Value: 9.22 Bil
PE Ratio: 22.97
PB Ratio: 4.50
GF Score: 91/100 
Exelixis Inc at Guggenheim Partners Healthcare Talks Oncology Days Transcript
Feb 11, 2021 / 04:30PM GMT
Release Date Price:
$22.07
(-4.17%)
Michael Werner Schmidt
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD
All right. Good morning. My name is Michael Schmidt, Senior Biotech Analyst with Guggenheim Securities. It is my pleasure to welcome Michael Morrissey, CEO of Exelixis, the next company that we'll be discussing now. Mike, thanks so much for joining us this year.
Michael M. Morrissey
Exelixis, Inc. - CEO, President & Director
You bet. Good morning.
Michael Werner Schmidt
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD
So I think most of us dialed into the earnings call last night, so some of this may still be fresh. But I still wanted to give you an opportunity to briefly highlight the company to those who might be new to the story.
Michael M. Morrissey
Exelixis, Inc. - CEO, President & Director
Fantastic. Well, good morning, everybody. Thanks for joining us today. Michael, thanks again for the invite. Great to be here.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers